CACNA1D and Parkinson disease: Isradipine, a brain-penetrant dihydropyridine calcium channel blocker capable of inhibiting both Cav1.2 and Cav1.3 channels, has recently been tested in the STEADY-PD Phase III study in PD; unfortunately, no benefit was observed [301].